{"title":"Prognostic value of serum phosphoglycerate dehydrogenase and glycine levels in breast cancer.","authors":"Hussam Abd Jassem, Anwar Jasib Thaaban","doi":"10.5114/pm.2024.140004","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer (BC) is the most frequent cancer in women and is a serious worldwide health issue. Phosphoglycerate dehydrogenase (PHGDH) is an enzyme that catalyses the first steps in the serine biosynthetic pathways downstream of glycolysis. Phosphoglycerate and glycine are produced by a series of enzymatic processes from the glycolysis intermediate 3-phosphoglycerate. The aim of the study was to indicate the levels of PHGDH and glycine in patients with breast cancer.</p><p><strong>Material and methods: </strong>The study was performed from December 2022 to March 2023. The total number of samples was 135 samples - 65 samples were collected from women with breast cancer, and 70 samples were from healthy women as a control group. Blood samples (5 ml) were obtained from all study group members. The complete blood count (CBC) neutrophils/lymphocytes, and haemoglobin ratio analysis was done on a CBC haematology analyser (Sysmex, Japan). Serum PHGDH and glycine were measure by enzyme-linked immunosorbent assay.</p><p><strong>Results: </strong>The study findings revealed a significant increase in the neutrophil/lymphocytes ratio and a decrease in PHGDH level in patients with BC compare to controls (p < 0.01), while the serum glycine level showed a significant increase in patients with BC compare to the control group (p < 0.01).</p><p><strong>Conclusions: </strong>Reduced PHGDH level and high glycine concentration in patients with BC could act as a prognostic factor in cancer development.</p>","PeriodicalId":55643,"journal":{"name":"Przeglad Menopauzalny","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11462141/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Przeglad Menopauzalny","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pm.2024.140004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Breast cancer (BC) is the most frequent cancer in women and is a serious worldwide health issue. Phosphoglycerate dehydrogenase (PHGDH) is an enzyme that catalyses the first steps in the serine biosynthetic pathways downstream of glycolysis. Phosphoglycerate and glycine are produced by a series of enzymatic processes from the glycolysis intermediate 3-phosphoglycerate. The aim of the study was to indicate the levels of PHGDH and glycine in patients with breast cancer.
Material and methods: The study was performed from December 2022 to March 2023. The total number of samples was 135 samples - 65 samples were collected from women with breast cancer, and 70 samples were from healthy women as a control group. Blood samples (5 ml) were obtained from all study group members. The complete blood count (CBC) neutrophils/lymphocytes, and haemoglobin ratio analysis was done on a CBC haematology analyser (Sysmex, Japan). Serum PHGDH and glycine were measure by enzyme-linked immunosorbent assay.
Results: The study findings revealed a significant increase in the neutrophil/lymphocytes ratio and a decrease in PHGDH level in patients with BC compare to controls (p < 0.01), while the serum glycine level showed a significant increase in patients with BC compare to the control group (p < 0.01).
Conclusions: Reduced PHGDH level and high glycine concentration in patients with BC could act as a prognostic factor in cancer development.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
